Non-invasive Detection of Volatile Metabolites in Parkinson's Disease

Summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder. Currently, a diagnostic test for early PD does not exist. The aim to address this problem by developing a non-invasive breath test to differentiate early PD from controls. Small molecules contained in breath, which offers precious information about disease presence, will be analysed. Data from the breath molecules and gut bacterial changes occurring in PD will be combined. These bacterial changes have been shown to arise years before the development of PD symptoms. Thanks to earlier diagnosis, therapies could start in advance and improve clinical outcomes and quality of life.

Eligibility

Inclusion Criteria \[PD group\]:

* (i) Patients undergoing neurological examination for confirmed or suspected Parkinson's disease
* (ii) Patients aged ≥18 years and below 90 years of age;
* (iii) Patients off antibiotic or probiotic therapies for at least the last 4 weeks;
* (iv) Patients without formal diagnosis of dysbiotic conditions;
* (v) Patients with capacity.

Inclusion Criteria \[Healthy Volunteers\]:

* (i) healthy volunteers that may be or not partner or carer of a Parkinson's patient;
* (ii) Subject aged ≥18 years and below 90 years of age;
* (iii) Patients off antibiotic or probiotic therapies for at least the last 4 weeks;
* (iv) Patients without formal diagnosis of dysbiotic conditions;
* (iiv) Subject with capacity.

Conditions2

Browse More Trials